

TEXAS CHILDREN'S HOSPITAL
EVIDENCE-BASED OUTCOMES CENTER
Skin & Soft Tissue Infection (SSTI)
Evidence-Based Guideline

Definition: Skin and soft tissue infection is a painful, erythematous infection of the dermis and subcutaneous tissue that has poorly demarcated borders and is characterized by an inflammatory response including: erythema, edema, lymphangitis, and advancing borders. The most common manifestation is abscess. ⁽¹⁻⁴⁾ Erysipelas is a form of cellulitis with marked superficial inflammation and sharply demarcated borders typically affecting the lower limbs and face. ⁽²⁾ Cellulitis, along with impetigo and folliculitis, is the 28th most common diagnosis in hospitalized patients. ⁽³⁾ *Staphylococcus aureus* is the most common cause of skin and soft tissue infection accounting for almost all cases of skin abscesses and up to 50% of cases of cellulitis. ⁽⁴⁾ Community-acquired methicillin-resistant *Staphylococcus aureus* (CA-MRSA) is of major concern accounting for approximately 25-30% of *S. aureus* isolated from hospitalized children in the geographic area surrounding Houston, Texas. ⁽⁵⁻⁹⁾ In 2020, 16% of all *S. aureus* isolates (MR and MS) from children with community acquired SSTI were clindamycin resistant. (Unpublished TCH Data)

Pathophysiology: When squamous epithelial cells with strong intercellular bonds, part of the integumentary barrier, are compromised bacteria are allowed to enter the dermis. Cellulitis is more serious in patients with underlying diseases such as diabetes or patients who are immunocompromised. ⁽¹⁰⁾

Inclusion Criteria

- Age >2 months

Exclusion Criteria

- Periorbital or perianal cellulitis
- Chronic wound
- Impetigo
- Folliculitis
- Fasciitis or deeper infection
- Lymphadenitis
- Diabetes
- Immunocompromise
- Sepsis
- Postoperative wound infection
- Infected animal bite
- Dental abscess
- Pregnancy

Differential Diagnosis

- Deeper infection (e.g., pyomyositis, septic arthritis, osteomyelitis)
- Thermal injuries
- Bug/Snake bites
- Sunburn, photodermatitis

Diagnostic Evaluation

Children with skin and soft tissue infection have a risk of progressing to septic shock.

Table 1. Vital Sign Changes of Sepsis ⁽¹¹⁾

Age	Heart Rate	Resp Rate	Systolic BP	Temp (°C)
0d - 1m	>205	>60	<60	<36 or >38
>1m - 3m	>205	>60	<70	<36 or >38
>3m - 1y	>190	>60	<70	<36 or >38.5
>1y - 2y	>190	>40	<70 + (age in yr x 2)	<36 or >38.5
>2y - 4y	>140	>40	<70 + (age in yr x 2)	<36 or >38.5
>4y - 6y	>140	>34	<70 + (age in yr x 2)	<36 or >38.5
>6y - 10y	>140	>30	<70 + (age in yr x 2)	<36 or >38.5
>10y - 13y	>100	>30	<90	<36 or >38.5
>13y	>100	>20	<90	<36 or >38.5

Table 2. Signs and Symptoms of Shock ⁽¹¹⁾

	Sign and/or Symptom
Peripheral Pulses	Decreased or weak Bounding
Capillary refill	≥ 3 sec Flash (< 1 sec)
Skin	Mottled, cool Flushed, ruddy, erythroderma (other than face) Petechiae below the nipple, any purpura
Mental status	Decreased, irritability, confusion inappropriate crying or drowsiness, poor interaction with parents, lethargy, diminished arousability, obtunded

History: Assess for

- Traumatic skin injury, tinea infection, leg ulcers, boils, etc.
- Query patient/parent about bite wounds, marine exposures, possibility of foreign body that can serve as a nidus for cellulitis

Physical Examination

- Evaluate for cardinal signs of infection: erythema, tenderness, pain, warmth, induration/edema, and drainage/fluctuance

Critical Points of Evidence*

Evidence Supports

- Obtain an ultrasound only when the diagnosis is equivocal. (12-19) – Strong recommendation, moderate quality evidence
- Consider the following options for cellulitis: Clindamycin (no age restriction), trimethoprim-sulfamethoxazole (children >2 months), or doxycycline (children ≥8 years only). If streptococcal infection is suspected, consider an alternative antibiotic to trimethoprim-sulfamethoxazole; if streptococcal infection is diagnosed, use penicillin or amoxicillin. Use caution when selecting clindamycin due to increased resistance rates in *S. aureus* isolates at TCH. Consider flavoring if administering PO clindamycin. (12,13,20-31) – Weak recommendation, low quality evidence
- Consider the following options for erysipelas: Clindamycin (no age restriction) or doxycycline (children ≥8 years only). Consider flavoring if administering PO clindamycin. (12,13,20-31) – Weak recommendation, low quality evidence
- Consider the following options for well-drained abscesses with overlying cellulitis, well-drained abscesses >3 cm, or well-drained abscesses with systemic symptoms (e.g., fever, vomiting): PO trimethoprim-sulfamethoxazole (preferred antibiotic; children >2 months only), PO doxycycline (children ≥8 years only), or PO clindamycin (no age restriction). PO cephalexin is a reasonable option for treating MSSA if contraindications preclude administering any of these options. Abscesses caused by Group A streptococcus are uncommon but if streptococcal infection is suspected, consider an alternative antibiotic to trimethoprim-sulfamethoxazole; if streptococcal infection is diagnosed, use penicillin or amoxicillin. Use caution when selecting clindamycin due to increased resistance rates in *S. aureus* isolates at TCH. Consider flavoring if administering PO clindamycin. (12,13,20-31) – Weak recommendation, low quality evidence
- Consider IV vancomycin for the following: large abscess or abscess involving critical area (e.g., face, hand), worsening clinical status, or concern for progression. Administer IV vancomycin if toxic or ill-appearing. Add IV nafcillin if the patient's condition is severe. (12,13,20-31) – Weak recommendation, low quality evidence
- Consider admission for the following: systemic symptoms (significant fever, SIRS), rapidly expanding or large lesion, age <3 months, concern for inadequate drainage of large abscess, abscess location that requires subspecialty consult, unable to tolerate oral antibiotics, significant pain, failed treatment with 48 hours of appropriate antibiotics, or follow-up concerns. (12,13,20,31,32) – Weak recommendation, very low quality evidence
- Consider dilute bleach baths, especially in cases of multiple recurrences. (20,33-35) – Weak recommendation, low quality evidence
- Consider whole-body washing with chlorhexidine to prevent recurrent abscesses. (20,33,36-44) – Weak recommendation, moderate quality evidence

Remarks: If doing both bleach baths and chlorhexidine washings, do not use chlorhexidine washes in bleach bath water as it can stain the skin brown. Alternate the days of bleach baths and chlorhexidine washings.

Evidence Against

- Do not routinely obtain blood cultures in children with SSTI. Obtain blood cultures in children with signs of systemic toxicity, rapidly spreading lesions, persistent fevers, or suspected deeper infection; consider obtaining blood cultures in children <3 months. (12,13,45-50) – Strong recommendation, very low quality evidence
- Do not obtain an ultrasound when the diagnosis is clear. (12-19) – Strong recommendation, moderate quality evidence
- Do not routinely administer antibiotics as an adjunct to I&D; consider administering antibiotics for systemic symptoms (e.g., fever, tachycardia, vomiting), overlying cellulitis, or abscess >3 cm. (12,13,20,51,52) – Strong recommendation, high quality evidence

Evidence Lacking/Inconclusive

- Consider additional imaging for admitted patients who are not improving on adequate antibiotics or if there is concern for new fluctuance or evolving abscess. (12,13) – Consensus recommendation
- Do not routinely use the following when administering antibiotics for SSTI: Linezolid (practical limitations) or IV trimethoprim-sulfamethoxazole. – Consensus recommendation
- Do not routinely administer prophylactic systemic antibiotics to prevent recurrence. (20,53) – Consensus recommendation

*NOTE: The references cited represent the entire body of evidence reviewed to make each recommendation.

Condition-Specific Elements of Clinical Management

Wound/Infection Management

- Measure and mark site and monitor for advancing area of involvement
- See treatment algorithm and antibiotic table for antibiotic options
- Monitor and manage pyrexia
- Elevate limb and use bed cradle, if applicable
- Utilize Contact Precautions for handling contaminated items
- If admitted, reevaluate patient frequently to determine need for further treatment or discharge readiness

Pain Management

- Assess need for pain management
- Provide oral/IV pain medications for I&D

Admission Criteria

Consider admission for:

- Systemic symptoms (significant fever, SIRS)
- Rapidly expanding or large lesions (>3 cm; significant cellulitis after abscess drainage)
- Age <3 months
- Concern for inadequate drainage of large abscess
- Abscess location that requires subspecialty consult
- Unable to tolerate oral antibiotics
- Significant pain
- Failed treatment with 48 hours of appropriate antibiotics
- Follow-up concerns

Discharge Criteria

- No fluctuance
- Erythema, size, and induration receding from outline
- Improving fever curve
- Tolerating oral intake
- Pain controlled with oral medications
- Ability to bear weight or use involved extremity

Consults/Referrals

- Consult surgery for I&D in the OR, if required

Prevention

- Strict handwashing
- Clean technique for dressing change

Measures

Process

- Type and duration of antibiotic administration (especially mupirocin and vancomycin)
- Appropriate laboratory tests and radiologic studies ordered
- Appropriate oral/IV pain management for I&D procedures performed outside of the OR
- Missed diagnosis of deeper process
- Use of dilute bleach baths
- Length of stay


Outcome

- EC visit within 7 days for SSTI
- Recurrent episodes requiring drainage

Antibiotic Table ⁽⁵⁴⁾

	Age Restrictions	Dose and Frequency
Trimethoprim (TMP) and Sulfamethoxazole (SMX) Simple SSTI (If proven group A strep, add PCN)	Children >2 months	<u>ORAL</u> : 4-6 mg TMP/kg/DOSE every 12 hours; MAX : 160 mg TMP/dose
Doxycycline Simple SSTI if suspect CA-MRSA	Children ≥8 years	<u>ORAL</u> : 1-2 mg/kg/DOSE every 12 hours; MAX : 100 mg/dose
Clindamycin (Refer to guidelines for clindamycin resistance rate)	None	<u>ORAL</u> : 10-13 mg/kg/dose every 8 h; MAX : 600 mg/DOSE <u>IV</u> : 10-13 mg/kg/dose every 8 h; MAX : 900 mg/DOSE
Cephalexin (For suspected/confirmed group A strep and MSSA)	None	<u>ORAL</u> : 12.5 mg/kg/DOSE every 6 hours; MAX : 500 mg/dose
Nafcillin (For suspected/confirmed MSSA)	None	<u>IV</u> : 37.5-50 mg/kg/DOSE every 6 hours; MAX : 12 grams/DAY
Vancomycin (For suspected/confirmed MRSA requiring IV therapy)	None	<u>IV</u> : 15 mg/kg/dose every 8h; MAX : 1 gram/dose For patients with invasive infection: 15 mg/kg/dose every 6 hours

TCH Evidence-Based Outcomes Center Clinical Algorithm for Skin & Soft Tissue Infection



References

1. Eron, L. J., Lipsky, B. A., Low, D. E., Nathwani, D., Tice, A. D., & Volturo, G. A. (2003). Managing skin and soft tissue infections: Expert panel recommendations on key decision points. *The Journal of Antimicrobial Chemotherapy*, 52(Suppl 1), i3-i17.
2. Morris, A. D. (2006). Cellulitis and erysipelas. *Clinical Evidence*, 15, 2207-2211.
3. Stulberg, D. L., Penrod, M. A., & Blatny, R. A. (2002). Common bacterial skin infections. *American Family Physician*, 66(1), 119.
4. Swartz, M. N. (2004). Cellulitis. *New England Journal of Medicine*, 350(9), 904-912.
5. Tien, I. M. D. (2006). Update on the management of skin, soft-tissue, and osteoarticular infections in children. *Current Opinion in Pediatrics*, 18(3), 254-259.
6. Kaplan, S. L., Hulten, K. G., Palazzi, D. L., Campbell, J. R., & Baker, C. J. (2005). Three-year surveillance of community-acquired Staphylococcus aureus infections in children. *Clinical Infectious Diseases*, 40(12), 1785-1791.
7. Mishaan, A. M. A., Mason, E. O. J., Martinez-Aguilar, G., Hammerman, W., Propst, J. J., Lupski, J. R., . . . Hulten, K. (2005). Emergence of a predominant clone of community-acquired Staphylococcus aureus among children in Houston, Texas. *Pediatric Infectious Disease Journal*, 24(3), 201-206.
8. Ochoa, T. J., Mohr, J., Wanger, A., Murphy, J. R., & Heresi, G. P. (2005). Community-associated methicillin-resistant Staphylococcus aureus in pediatric patients. *Emerging Infectious Diseases*, 11(6), 966-968.
9. Parchman, M. L., & Munoz, A. (2009). Risk factors for methicillin-resistant Staphylococcal aureus skin and soft tissue infections presenting in primary care: A South Texas Ambulatory Research Network (STARNet) study. *Journal of the American Board of Family Medicine*, 22(4), 375-379.
10. Cunningham, D., Edelman, R., Talvera, F., Sanders, C. V., & Elefthe, C. B. A. (2007). Cellulitis. *Medicine from WebMD*, 1-17.
11. American Heart Association & American Academy of Pediatrics. (2016). Pediatric Advanced Life Support: Provider Manual. Dallas, TX: American Heart Association.
12. Children's Hospital of Philadelphia. (2015). Cellulitis/Abscess, suspected.
13. Seattle Children's Hospital. (2013). Cellulitis and abscess.
14. Adams, C. M., Neuman, M. I., & Levy, J. A. (2016). Point-of-care ultrasonography for the diagnosis of pediatric soft tissue infection. *Journal of Pediatrics*, 169, 122-127.e1.
15. Iverson, K., Haritos, D., Thomas, R., & Kannikeswaran, N. (2012). The effect of bedside ultrasound on diagnosis and management of soft tissue infections in a pediatric ED. *American Journal of Emergency Medicine*, 30(8), 1347-1351.
16. Marin, J., Dean, A., Bilker, W., Panebianco, N., Brown, N., & Alpern, E. (2013). Emergency ultrasound-assisted examination of skin and soft tissue infections in the pediatric emergency department. *Academic Emergency Medicine*, 20(6), 545-553.
17. Sivitz, A. B., Lam, S. H., Ramirez-Schrempp, D., Valente, J. H., & Nagdev, A. D. (2010). Effect of bedside ultrasound on management of pediatric soft-tissue infection. *Journal of Emergency Medicine*, 39(5), 637-643.
18. Subramaniam, S., Bober, J., Chao, J., & Zehtabchi, S. (2016). Point-of-care ultrasound for diagnosis of abscess in skin and soft tissue infections. *Academic Emergency Medicine*, 23(11), 1298-1306.
19. Tayal, V. S., Hasan, N., Norton, H. J., & Tomaszewski, C. A. (2006). The effect of soft-tissue ultrasound on the management of cellulitis in the emergency department. *Academic Emergency Medicine*, 13(4), 384.
20. Stevens, D. L., Bisno, A. L., Chambers, H. F., Patchen Dellinger, E., Goldstein, E. J. C., Gorbach, S. L., . . . Wade, J. C. (2014). Practice guidelines for the diagnosis and management of skin and soft tissue infections: 2014 update by the Infectious Diseases Society of America.
21. Cenizal, M. J., Skiest, D., Luber, S., Bedimo, R., Davis, P., Fox, P., . . . Hardy, R. D. (2007). Prospective randomized trial of empiric therapy with trimethoprim-sulfamethoxazole or doxycycline for outpatient skin and soft tissue infections in an area of high prevalence of methicillin-resistant Staphylococcus aureus. *Antimicrobial Agents and Chemotherapy*, 51(7), 2628-2630.
22. Chen, A. E., Carroll, K. C., Diener-West, M., Ross, T., Ordu, J., Goldstein, M. A., . . . Siberry, G. K. (2011). Randomized controlled trial of cephalexin versus clindamycin for uncomplicated pediatric skin infections. *Pediatrics*, 127(3), e573-580.
23. Elliott, D. J., Zaoutis, T. E., Troxel, A. B., Loh, A., & Keren, R. (2009). Empiric antimicrobial therapy for pediatric skin and soft-tissue infections in the era of methicillin-resistant Staphylococcus aureus. *Pediatrics*, 123(6), e959-966.
24. Falagas, M. E., Matthaiou, D. K., & Vardakas, K. Z. (2006). Fluoroquinolones vs beta-lactams for empirical treatment of immunocompetent patients with skin and soft tissue infections: A meta-analysis of randomized controlled trials. *Mayo Clinic Proceedings*, 81(12), 1553-1566.
25. Hyun, D. Y., Mason, E. O., Forbes, A., & Kaplan, S. L. (2009). Trimethoprim-sulfamethoxazole or clindamycin for treatment of community-acquired methicillin-resistant Staphylococcus aureus skin and soft tissue infections. *Pediatric Infectious Disease Journal*, 28(1), 57-59.
26. Kilburn, S. A., Featherstone, P., Higgins, B., & Brindle, R. (2010). Interventions for cellulitis and erysipelas. *Cochrane Database of Systematic Reviews*, 2010(6), CD004299.
27. Miller, L. G., Daum, R. S., Creech, C. B., Young, D., Downing, M. D., Eells, S. J., . . . Chambers, H. F. (2015). Clindamycin versus trimethoprim-sulfamethoxazole for uncomplicated skin infections. *New England Journal of Medicine*, 372(12), 1093-1103.
28. Pallin, D. J., Binder, W. D., Allen, M. B., Lederman, M., Parmar, S., Filbin, M. R., . . . Camargo, C. A., Jr. (2013). Clinical trial: Comparative effectiveness of cephalexin plus trimethoprim-sulfamethoxazole versus cephalexin alone for treatment of uncomplicated cellulitis: A randomized controlled trial. *Clinical Infectious Diseases*, 56(12), 1754-1762.
29. Wells, R. D., Mason, P., Roarty, J., & Dooley, M. (2009). Comparison of initial antibiotic choice and treatment of cellulitis in the pre- and post-community-acquired methicillin-resistant Staphylococcus aureus eras. *The American Journal of Emergency Medicine*, 27(4), 436-439.
30. Williams, D. J., Cooper, W. O., Kaltenbach, L. A., Dudley, J. A., Kirschke, D. L., Jones, T. F., . . . Creech, C. B. (2011). Comparative effectiveness of antibiotic treatment strategies for pediatric skin and soft-tissue infections. *Pediatrics*, 128(3), e479-487.
31. Yusuf, S., Hagan, J. L., & Adekunle-Ojo, A. O. (2016) Managing skin and soft tissue infections in the emergency department observation unit. *Pediatric Emergency Care*, epub ahead of print.
32. Lane, R. D., Sandweiss, D. R., & Corneli, H. M. (2014). Treatment of skin and soft tissue infections in a pediatric observation unit. *Clinical Pediatrics*, 53(5), 439-443.
33. Fritz, S. A., Camins, B. C., Eisenstein, K. A., Fritz, J. M., Epplin, E. K., Burnham, C. A., . . . Storch, G. A. (2011). Effectiveness of measures to eradicate Staphylococcus aureus carriage in patients with community-associated skin and soft-tissue infections: A randomized trial. *Infection Control and Hospital Epidemiology*, 32(9), 872-880.
34. Huang, J. T., Abrams, M., Tloughan, B., Rademaker, A., & Paller, A. S. (2009). Treatment of Staphylococcus aureus colonization in atopic dermatitis decreases disease severity. *Pediatrics*, 123(5), e808-e814.
35. Kaplan, S. L., Forbes, A., Hammerman, W. A., Lamberth, L., Hulten, K. G., Minard, C. G., & Mason, E. O. (2014). Randomized trial of "bleach baths" plus routine hygienic measures vs. routine hygienic measures alone for prevention of recurrent infections. *Clinical Infectious Diseases*, 58(5), 679-682.
36. Batra, R., Cooper, B. S., Whiteley, C., Patel, A. K., Wyncoll, D., & Edgeworth, J. D. (2010). Efficacy and limitation of a chlorhexidine-based decolonization strategy in preventing transmission of methicillin-resistant Staphylococcus aureus in an intensive care unit. *Clinical Infectious Diseases*, 50(2), 210-217.
37. Climo, M. W., Sepkowitz, K. A., Zuccotti, G., Fraser, V. J., Warren, D. K., Perl, T. M., . . . Wong, E. S. (2009). The effect of daily bathing with chlorhexidine on the acquisition of methicillin-resistant Staphylococcus aureus, vancomycin-resistant Enterococcus, and healthcare-associated bloodstream infections: Results of a quasi-experimental multicenter trial. *Critical Care Medicine*, 37(6), 1858-1865.

38. Ellis, M. W., Schlett, C. D., Millar, E. V., Wilkins, K. J., Crawford, K. B., Morrison-Rodriguez, S. M., . . . Tribble, D. R. (2014). Hygiene strategies to prevent methicillin-resistant *Staphylococcus aureus* skin and soft tissue infections: A cluster-randomized controlled trial among high-risk military trainees. *Clinical Infectious Diseases*, *58*(11), 1540-1548.
39. Fritz, S. A., Hogan, P. G., Hayek, G., Eisenstein, K. A., Rodriguez, M., Epplin, E. K., . . . Fraser, V. J. (2012). Household versus individual approaches to eradication of community-associated *Staphylococcus aureus* in children: A randomized trial. *Clinical Infectious Diseases*, *54*(6), 743-751.
40. Millar, E. V., Chen, W. J., Schlett, C. D., Cui, T., Crawford, K. B., Lanier, J. B., . . . Ellis, M. W. (2015). Frequent use of chlorhexidine-based body wash associated with a reduction in methicillin-resistant *Staphylococcus aureus* nasal colonization among military trainees. *Antimicrobial Agents and Chemotherapy*, *59*(2), 943-949.
41. Ridenour, G., Lampen, R., Federspiel, J., Kritchevsky, S., Wong, E., & Climo, M. (2007). Selective use of intranasal mupirocin and chlorhexidine bathing and the incidence of methicillin-resistant *Staphylococcus aureus* colonization and infection among Intensive Care Unit patients. *Infection Control and Hospital Epidemiology*, *28*(10), 1155-1161.
42. Simor, A. E., Phillips, E., McGeer, A., Konvalinka, A., Loeb, M., Devlin, H. R., & Kiss, A. (2007). Randomized controlled trial of chlorhexidine gluconate for washing, intranasal mupirocin, and rifampin and doxycycline versus no treatment for the eradication of methicillin-resistant *Staphylococcus aureus* colonization. *Clinical Infectious Diseases*, *44*(2), 178-185.
43. Wendt, C., Schinke, S., Wurttemberger, M., Oberdorfer, K., Bock-Hensley, O., & von Baum, H. (2007). Value of whole-body washing with chlorhexidine for the eradication of methicillin-resistant *Staphylococcus aureus*: A randomized, placebo-controlled, double-blind clinical trial. *Infection Control and Hospital Epidemiology*, *28*(9), 1036-1043.
44. Whitman, T. J., Herlihy, R. K., Schlett, C. D., Murray, P. R., Grandits, G. A., Ganesan, A., . . . Tribble, D. R. (2010). Chlorhexidine-impregnated cloths to prevent skin and soft-tissue infection in Marine recruits: A cluster-randomized, double-blind, controlled effectiveness trial. *Infection Control and Hospital Epidemiology*, *31*(12), 1207-1215.
45. Astete, J. A., Battle, A., Hernandez-Bou, S., Trenchs, V., Gene, A., & Luaces, C. (2014). Blood culture diagnostic yield in a paediatric emergency department. *European Journal of Emergency Medicine*, *21*(5), 336-340.
46. Malone, J. R., Durica, S. R., Thompson, D. M., Bogie, A., & Naifeh, M. (2013). Blood cultures in the evaluation of uncomplicated skin and soft tissue infections. *Pediatrics*, *132*(3), 454-459.
47. Parikh, K., Davis, A. B., & Pavuluri, P. (2014). Do we need this blood culture? *Hospital Pediatrics*, *4*(2), 78-84.
48. Sadow, K. B., & Chamberlain, J. M. (1998). Blood cultures in the evaluation of children with cellulitis. *Pediatrics*, *101*(3), e4.
49. Trenchs, V., Hernandez-Bou, S., Bianchi, C., Arnan, M., Gene, A., & Luaces, C. (2015). Blood cultures are not useful in the evaluation of children with uncomplicated superficial skin and soft tissue infections. *Pediatric Infectious Disease Journal*, *34*(9), 924-927.
50. Wathen, D., & Halloran, D. R. (2013). Blood culture associations in children with a diagnosis of cellulitis in the era of methicillin-resistant *Staphylococcus aureus*. *Hospital Pediatrics*, *3*(2), 103-107.
51. Duong, M., Markwell, S., Peter, J., & Barenkamp, S. (2009). Randomized, controlled trial of antibiotics in the management of community-acquired skin abscesses in the pediatric patient. *Annals of Emergency Medicine*, *55*(5), 401-407.
52. Singer, A. J., & Thode, H. C., Jr. (2014). Systemic antibiotics after incision and drainage of simple abscesses: A meta-analysis. *Emergency Medicine Journal*, *31*(7), 567-578.
53. Oh, C. C., Ko, H. C. H., Lee, H. Y., Safdar, N. Maki, D. G., & Chlebicki, M. P. (2014). Antibiotic prophylaxis for preventing recurrent cellulitis: A systematic review and meta-analysis. *Journal of Infection*, *69*, 26-34.
54. Texas Children's Hospital Drug Information and Formulary. 13th ed. Hudson (OH): Lexicomp; 2017.

Clinical Standards Preparation

This clinical standard was prepared by the Evidence-Based Outcomes Center (EBOC) team in collaboration with content experts at Texas Children’s Hospital. Development of this clinical standard supports the TCH Quality and Patient Safety Program initiative to promote clinical standards and outcomes that build a culture of quality and safety within the organization.

SSTI Content Expert Team

- Kiyetta Alade, MD, Emergency Medicine
- Rathi Asaithambi, MD, Pediatrics
- Corrie Chumpitazi, MD, Emergency Medicine
- Beth D’Amico, MD, Emergency Medicine
- Mindy Fein, MD, Emergency Medicine
- Carol Green, MD, House Staff
- Herman Kan, MD, Radiology
- Chase McNeil, MD, Infectious Diseases
- Kamini Muzumdar, MD, Texas Children’s Pediatrics
- Debra Palazzi, MD, Infectious Diseases
- Autumn Pruette, MD, TCPA
- Kristy Rialon, MD, Surgery
- Barbara Richardson, RN, Wound Ostomy Continence
- Brittany Rodriguez, PharmD, Pharmacy
- Geeta Singhal, MD, Pediatric Hospital Medicine
- Grant Stimes, PharmD, Pharmacy
- Matthew Wilber, MD, TCP
- Shabana Yusuf, MD, Emergency Medicine

EBOC Team

- Andrea Jackson, MBA, RN, Evidence-Based Practice Specialist
- Betsy Lewis, MSN, RN, CNL, Evidence-Based Practice Specialist
- Sheesha Porter, MS, RN, Evidence-Based Practice Specialist
- Anne Dykes, MSN, RN, Manager
- Binita Patel, MD, Medical Director

The following financial and/or intellectual conflict was identified and addressed to ensure objectivity: Shabana Yusuf was the lead author of a study included in the literature review.

Development Process

This clinical standard was developed using the process outlined in the EBOC Manual. The literature appraisal documents the following steps:

1. Review Preparation
 - PICO questions established
 - Evidence search confirmed with content experts
2. Review of Existing External Guidelines
 - IDSA (2014) Diagnosis and Management of Skin and Soft Tissue Infections; Children’s Hospital of Philadelphia (2015) Cellulitis/Abscess, Suspected; Seattle Children’s Hospital (2013) Cellulitis and Abscess
3. Literature Review of Relevant Evidence
 - Searched: PubMed, Cochrane
4. Critically Analyze the Evidence
 - 4 meta-analyses, 14 randomized controlled trials, and 20 nonrandomized studies
5. Summarize the Evidence
 - Materials used in the development of the clinical standard, literature appraisal, and any order sets are maintained in an SSTI evidence-based review manual within EBOC.

Evaluating the Quality of the Evidence

Published clinical guidelines were evaluated for this review using the **AGREE II** criteria. The summary of these guidelines are included in the literature appraisal. AGREE II criteria evaluate Guideline Scope and Purpose, Stakeholder Involvement, Rigor of Development, Clarity and Presentation, Applicability, and Editorial Independence using a 4-point Likert scale. The higher the score, the more comprehensive the guideline.

This clinical standard specifically summarizes the evidence *in support of* or *against* specific interventions and identifies where

evidence is *lacking/inconclusive*. The following categories describe how research findings provide support for treatment interventions. **“Evidence Supports”** provides evidence to support an intervention. **“Evidence Against”** provides evidence against an intervention. **“Evidence Lacking/Inconclusive”** indicates there is insufficient evidence to support or refute an intervention and no conclusion can be drawn *from the evidence*.

The **GRADE** criteria were utilized to evaluate the body of evidence used to make practice recommendations. The table below defines how the quality of the evidence is rated and how a strong versus weak recommendation is established. The literature appraisal reflects the critical points of evidence.

Recommendation	
STRONG	Desirable effects clearly outweigh undesirable effects or vice versa
WEAK	Desirable effects closely balanced with undesirable effects
Quality	Type of Evidence
High	Consistent evidence from well-performed RCTs or exceptionally strong evidence from unbiased observational studies
Moderate	Evidence from RCTs with important limitations (e.g., inconsistent results, methodological flaws, indirect evidence, or imprecise results) or unusually strong evidence from unbiased observational studies
Low	Evidence for at least 1 critical outcome from observational studies, RCTs with serious flaws or indirect evidence
Very Low	Evidence for at least 1 critical outcome from unsystematic clinical observations or very indirect evidence

Recommendations

Practice recommendations were directed by the existing evidence and consensus amongst the content experts. Patient and family preferences were included when possible. The Content Expert Team and EBOC team remain aware of the controversies in the diagnosis and management of SSTI in children. When evidence is lacking, options in care are provided in the clinical standard and the accompanying order sets (if applicable).

Approval Process

Clinical standards are reviewed and approved by hospital committees as deemed appropriate for its intended use. Clinical standards are reviewed as necessary within EBOC at Texas Children’s Hospital. Content Expert Teams are involved with every review and update.

Disclaimer

Practice recommendations are based upon the evidence available at the time the clinical standard was developed. Clinical standards (guidelines, summaries, or pathways) **do not** set out the standard of care, and are not intended to be used to dictate a course of care. Each physician/practitioner must use his or her independent judgment in the management of any specific patient and is responsible, in consultation with the patient and/or the patient family, to make the ultimate judgment regarding care.

Version History

Date	Comments
Jun 2010	Originally completed
Jun 2017	Updated
April 2018	Revised the algorithm and discharge criteria
Jan 2019	Revised the ‘Vital Signs Changes of Sepsis’ table
Nov 2020	Updated Antibiotic Table
Sept 2021	Updated Signs and Symptoms of Shock Table
June 2022	Reaffirmed with updates; Updated antibiotic table; Updated algorithm with NPO policy link and clear liquid diet